A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

Sagar Sardesai(The Ohio State University Wexner Medical Center), Robert Wesolowski(The Ohio State University), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Yonghua Ling(The Ohio State University), Daniel G. Stover(Harvard University), Michael R. Grever(The Ohio State University Wexner Medical Center), Mohamed Badawi(The Ohio State University), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jeffrey VanDeusen(The Ohio State University), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Lai Wei(Tongji University), Mitch A. Phelps(The Ohio State University), Bhuvaneswari Ramaswamy(The Ohio State University), Evan Morgan(The Ohio State University), Mathew Cherian(The Ohio State University Wexner Medical Center), Raquel E. Reinbolt(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Mahmoud Kassem(The Ohio State University), Nicole Williams(The Ohio State University), Julie Stephens(The Ohio State University)
Investigational New Drugs
January 17, 2020
Cited by 37


Related Papers